150 related articles for article (PubMed ID: 34325303)
1. Metabolic benefits of novel histamine H
Mika K; Szafarz M; Bednarski M; Kuder K; Szczepańska K; Pociecha K; Pomierny B; Kieć-Kononowicz K; Sapa J; Kotańska M
Biomed Pharmacother; 2021 Oct; 142():111952. PubMed ID: 34325303
[TBL] [Abstract][Full Text] [Related]
2. Histamine H
Mika K; Szafarz M; Bednarski M; Latacz G; Sudoł S; Handzlik J; Pociecha K; Knutelska J; Nicosia N; Szczepańska K; Kuder KJ; Kieć-Kononowicz K; Kotańska M
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832862
[TBL] [Abstract][Full Text] [Related]
3. KSK-74: Dual Histamine H
Mika K; Szafarz M; Zadrożna M; Nowak B; Bednarski M; Szczepańska K; Pociecha K; Kubacka M; Nicosia N; Juda I; Kieć-Kononowicz K; Kotańska M
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806019
[TBL] [Abstract][Full Text] [Related]
4. KSK19 - Novel histamine H3 receptor ligand reduces body weight in diet induced obese mice.
Kotańska M; Mika K; Reguła K; Szczepańska K; Szafarz M; Bednarski M; Olejarz-Maciej A; Nowak K; Latacz G; Mogilski S; Kuder KJ; Kieć-Kononowicz K; Sapa J
Biochem Pharmacol; 2019 Oct; 168():193-203. PubMed ID: 31295465
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Some Safety Parameters of Dual Histamine H
Mika K; Szafarz M; Bednarski M; Siwek A; Szczepańska K; Kieć-Kononowicz K; Kotańska M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108661
[TBL] [Abstract][Full Text] [Related]
6. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides.
Malmlöf K; Golozoubova V; Peschke B; Wulff BS; Refsgaard HH; Johansen PB; Cremers T; Rimvall K
Obesity (Silver Spring); 2006 Dec; 14(12):2154-62. PubMed ID: 17189541
[TBL] [Abstract][Full Text] [Related]
7. The H3 receptor is involved in cholecystokinin inhibition of food intake in rats.
Attoub S; Moizo L; Sobhani I; Laigneau JP; Lewin MJ; Bado A
Life Sci; 2001 Jun; 69(4):469-78. PubMed ID: 11459437
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
10. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
Hancock AA; Brune ME
Expert Opin Investig Drugs; 2005 Mar; 14(3):223-41. PubMed ID: 15833055
[TBL] [Abstract][Full Text] [Related]
11. Recent medicinal chemistry of the histamine H3 receptor.
Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
[No Abstract] [Full Text] [Related]
12. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
13. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.
Takahashi K; Suwa H; Ishikawa T; Kotani H
J Clin Invest; 2002 Dec; 110(12):1791-9. PubMed ID: 12488429
[TBL] [Abstract][Full Text] [Related]
14. The histamine H
Kotańska M; Kuder KJ; Szczepańska K; Sapa J; Kieć-Kononowicz K
Naunyn Schmiedebergs Arch Pharmacol; 2018 Aug; 391(8):875-881. PubMed ID: 29802412
[TBL] [Abstract][Full Text] [Related]
15. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight.
Malmlöf K; Zaragoza F; Golozoubova V; Refsgaard HH; Cremers T; Raun K; Wulff BS; Johansen PB; Westerink B; Rimvall K
Int J Obes (Lond); 2005 Dec; 29(12):1402-12. PubMed ID: 16151415
[TBL] [Abstract][Full Text] [Related]
16. Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity.
Masaki T; Yoshimatsu H
Curr Med Chem; 2010; 17(36):4587-92. PubMed ID: 21062248
[TBL] [Abstract][Full Text] [Related]
17. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
[No Abstract] [Full Text] [Related]
18. Guided rational design with scaffold hopping leading to novel histamine H
Ghamari N; Kouhi Hargelan S; Zivkovic A; Leitzbach L; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Bioorg Chem; 2021 Dec; 117():105411. PubMed ID: 34653944
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.
Yoshimoto R; Miyamoto Y; Shimamura K; Ishihara A; Takahashi K; Kotani H; Chen AS; Chen HY; Macneil DJ; Kanatani A; Tokita S
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13866-71. PubMed ID: 16954192
[TBL] [Abstract][Full Text] [Related]
20. Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats.
Mika K; Szafarz M; Sapa J; Kotańska M
Biomed Pharmacother; 2021 Sep; 141():111892. PubMed ID: 34229247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
